Moody Aldrich Partners LLC Sells 60,990 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Moody Aldrich Partners LLC trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 22.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 215,657 shares of the biopharmaceutical company's stock after selling 60,990 shares during the period. Moody Aldrich Partners LLC owned 0.18% of Catalyst Pharmaceuticals worth $4,501,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock valued at $8,116,000 after purchasing an additional 33,888 shares during the last quarter. Wellington Management Group LLP bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $1,185,000. Redhawk Wealth Advisors Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $1,273,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth $258,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at $625,000. Institutional investors own 79.22% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Bank of America reiterated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. StockNews.com lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, January 11th. HC Wainwright lifted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, January 10th. Finally, Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an "overweight" rating and a $35.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $32.86.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX traded down $0.63 during midday trading on Friday, reaching $22.56. 1,051,439 shares of the stock were exchanged, compared to its average volume of 1,378,861. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.12 and a 12 month high of $24.64. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of 19.12, a P/E/G ratio of 2.39 and a beta of 0.79. The business has a 50-day simple moving average of $21.98 and a two-hundred day simple moving average of $20.72.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares of the company's stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.